Can Probiotics, Particularly <i>Limosilactobacillus fermentum</i> UCO-979C and <i>Lacticaseibacillus rhamnosus</i> UCO-25A, Be Preventive Alternatives against SARS-CoV-2?
2023
Héctor Valdebenito-Navarrete | Victor Fuentes-Barrera | Carlos T. Smith | Alexis Salas-Burgos | Felipe A. Zuniga | Leonardo A. Gomez | Apolinaria García-Cancino
COVID-19, an infection produced by the SARS-CoV-2 virus in humans, has rapidly spread to become a high-mortality pandemic. SARS-CoV-2 is a single-stranded RNA virus characterized by infecting epithelial cells of the intestine and lungs, binding to the ACE2 receptor present on epithelial cells. COVID-19 treatment is based on antivirals and antibiotics against symptomatology in addition to a successful preventive strategy based on vaccination. At this point, several variants of the virus have emerged, altering the effectiveness of treatments and thereby attracting attention to several alternative therapies, including immunobiotics, to cope with the problem. This review, based on articles, patents, and an in silico analysis, aims to address our present knowledge of the COVID-19 disease, its symptomatology, and the possible beneficial effects for patients if probiotics with the characteristics of immunobiotics are used to confront this disease. Moreover, two probiotic strains, <i>L. fermentum</i> UCO-979C and <i>L. rhamnosus</i> UCO-25A, with different effects demonstrated at our laboratory, are emphasized. The point of view of this review highlights the possible benefits of probiotics, particularly those associated with immunomodulation as well as the production of secondary metabolites, and their potential targets during SARS-CoV-2 infection.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals